Skip to main
PEPG

PepGen Inc (PEPG) Stock Forecast & Price Target

PepGen Inc (PEPG) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PepGen is a clinical-stage biotechnology company with a promising Enhanced Delivery Oligonucleotide platform that has shown potential in delivering oligonucleotide therapeutics to various target tissues. The company's financial results for the first quarter of 2026 show a positive trend and its cash reserves provide a promising runway for future developments. Despite minor adjustments to estimates, the company's target price is still high and maintains an Outperform rating, with the upcoming 10mg/kg PGN-EDODM1 data in the second half of 2026 being a key catalyst. However, potential challenges in financing, commercial execution, and competition, as well as safety concerns, should be monitored.

Bears say

PepGen is a clinical-stage biotechnology company that has developed an Enhanced Delivery Oligonucleotide platform for better delivery of therapeutics. Despite promising pipeline products, the company has a reported negative GAAP EPS and may struggle with obtaining funding and gaining regulatory approval. Additionally, early data on their lead product, PGN-EDODM1, is complicated and has shown some potential safety concerns. This, coupled with a decrease in fair value estimates from $9 to $5, indicates a negative outlook for PepGen's stock.

PepGen Inc (PEPG) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PepGen Inc (PEPG) Forecast

Analysts have given PepGen Inc (PEPG) a Strong Buy based on their latest research and market trends.

According to 6 analysts, PepGen Inc (PEPG) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PepGen Inc (PEPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.